In the craft-beer industry, the majority of hops — the flowers used in production that add bitterness and aroma to the product — come from the Pacific Northwest region.
Could Maryland, too, be a fertile region for hops?
GlaxoSmithKline will cut more than 30 drug development programmes and may sell its rare diseases unit, as the FTSE 100 group seeks to inject more “edge and pace” into its decision making, its new chief executive Emma Walmsley has said.
The day after emocha® Mobile Health, Inc., launched in 2013, CEO Sebastian Seiguer (pronounced SAY-ger) heard about a 3-year-old tuberculosis (TB) patient being treated at a Baltimore clinic. Maryland requires healthcare providers to watch patients take every dose of their medication for active TB treatment, an approach known as directly observed therapy (DOT). But coordinating with the clinic every day was proving too difficult for the girl’s mother to manage. To keep up with the treatments, she would have had to quit her job.
No area is hotter or attracting more dollars in pharma than immuno-oncology–the idea of harnessing the immune system to fight cancer. My fellow Forbes contributor Bruce Booth has recently characterized the intensifying interest in this space as the “exploding supernova” of cancer research.
Emergent BioSolutions Inc. (NYSE:EBS) today announced a licensing agreement with Valneva SE for global exclusive rights to Valneva’s Zika vaccine technology, ZIKV. Emergent and Valneva will co-develop ZIKV-VLA1601, a highly purified inactivated vaccine candidate against the Zika virus, from preclinical development through completion of a Phase 1 safety and immunogenicity clinical trial. ZIKV-VLA1601, which has shown to elicit functional antibody responses, is based on Valneva’s established inactivated, whole virus manufacturing platform on which its licensed Japanese Encephalitis vaccine was developed and produced.
IonQ, an early-stage company developing quantum computing for commercial applications, today announced completion of a $20 million series B round led by New Enterprise Associates (NEA) and GV (formerly Google Ventures), with participation from new strategic investors. Building on the pioneering work of world-renowned experts at the University of Maryland and Duke University, IonQ plans to bring general-purpose quantum computers to market by late 2018.
A new type of trial design can help the healthcare industry bring beneficial therapies to patients sooner and stop researching inferior ones earlier.
Value has found a place at the heart of healthcare innovation. For money-conscious governments and other actors in the system, it’s not enough that a new treatment be beneficial and safe. It also needs to be cost effective.
Calling All Medical Device Innovators!
We are now accepting proposals for our annual $250K pediatric medical device pitch competition. Up to six innovations will be awarded up to $50,000 each during our 5th Annual Pediatric Surgical Innovation Symposium.
Registration Open – 5th Annual Pediatric Device Innovation Symposium We are pleased to announce that our 5th annual Pediatric Device Innovation Symposium, “Partnering for Breakthroughs in Pediatric Surgery and Care,” is co-locating in San Jose, California in a joint effort with The MedTech Conference powered by AdvaMed – the premiere gathering of medtech professionals in North America.
Join us Sunday, September 24, 2017
Here are some of the event highlights:
Keynotes and panels on topics related to pediatric device innovation Make your Medical Device Pitch for Kids! competition – $250K in funding Invaluable networking opportunities to meet, learn and get inspired by your fellow medtech innovators Special savings when you attend the Symposium and The MedTech Conference
About the Cluster Action Plan TOHealth! brought together diverse participants from Human Health and Sciences ecosystem in the Toronto region to develop Ontario’s first draft Cluster Action Plan under the Partnerships for Jobs and Growth Act. The draft Plan has been approved by the Minister of Economic Development and Growth / Research Innovation and Science and is now subject to a 30 day public consultation. Please download the draft documents using links above and share your comments using the button below. The consultation period ends August 11, 2017.
The Galien Foundation announced today the 2017 Annual Prix Galien USA Awards Nominees.
Worldwide regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research, the Prix Galien recognizes outstanding biomedical and technology product achievement that improves the human condition.